Clinical Trial Update: Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation [Phase 1]

View source ↗

Summary

Phase 1 trial assessing Capmatinib plus Trametinib for metastatic non-small cell lung cancer with MET exon 14 skipping mutation; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Capmatinib (capmatinib)
• Trametinib (trametinib)

Snippet

Sponsor: Collin Blakely | Conditions: Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer | Phase 1 | Status: TERMINATED